{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:18Z","timestamp":1787020698186,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13011-019-0206-5","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:06:58Z","timestamp":1558001218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Anabolic-androgenic steroid users receiving health-related information; health problems, motivations to quit and treatment desires"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0065","authenticated-orcid":false,"given":"Ingrid Amalia","family":"Havnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Lindvik","family":"J\u00f8rstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wisl\u00f8ff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"206_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/bjp.2008.165","volume":"154","author":"A Kicman","year":"2008","unstructured":"Kicman A. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154:502\u201321.","journal-title":"Br J Pharmacol"},{"key":"206_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1210\/er.2013-1058","volume":"35","author":"HG Pope","year":"2013","unstructured":"Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2013;35:341\u201375.","journal-title":"Endocr Rev"},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jama.2016.17441","volume":"317","author":"HG Pope","year":"2017","unstructured":"Pope HG, Khalsa JH, Bhasin S. Body image disorders and abuse of anabolic-androgenic steroids among men. JAMA. 2017;317:23\u20134.","journal-title":"JAMA."},{"key":"206_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mce.2017.02.039","volume":"464","author":"G Kanayama","year":"2018","unstructured":"Kanayama G, Pope HG. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4\u201313.","journal-title":"Mol Cell Endocrinol"},{"key":"206_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1521-0391.2013.12118.x","volume":"23","author":"HG Pope","year":"2014","unstructured":"Pope HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014;23:371\u20137.","journal-title":"Am J Addict"},{"key":"206_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","volume":"24","author":"D Sagoe","year":"2014","unstructured":"Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24:383\u201398.","journal-title":"Ann Epidemiol"},{"key":"206_CR7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MED.0000000000000403","volume":"25","author":"D Sagoe","year":"2018","unstructured":"Sagoe D, Pallesen S. Androgen abuse epidemiology. Current Opinion in Endocrinology & Diabetes and Obesity. 2018;25:185\u201394.","journal-title":"Current Opinion in Endocrinology & Diabetes and Obesity"},{"key":"206_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jsams.2017.03.008","volume":"20","author":"AL Bagge","year":"2017","unstructured":"Bagge AL, Ros\u00e9n T, Fahlke C, Ehrnborg C, Eriksson B, Moberg T, Thiblin I. Somatic effects of AAS abuse: a 30-years follow-up study of male former power sports athletes. J Sci Med Sport. 2017;20:814\u20138.","journal-title":"J Sci Med Sport"},{"key":"206_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1136\/bjsports-2012-091340","volume":"47","author":"A Lindqvist","year":"2013","unstructured":"Lindqvist A, Moberg T, Eriksson B, Ehrnborg C, Ros\u00e9n T, Fahlke C. A retrospective 30-year follow-up study of former Swedish-elite male athletes in power sports with a past anabolic androgenic steroids use: a focus on mental health. British Journal of Sports Medisine. 2013;47:965\u20139.","journal-title":"British Journal of Sports Medisine"},{"key":"206_CR10","first-page":"278","volume":"24","author":"J McVeigh","year":"2017","unstructured":"McVeigh J, Begley E. Anabolic steroids in the UK. An increasing issue for public health. Drugs: Education, Prevention and Policy. 2017;24:278\u201385.","journal-title":"Drugs: Education, Prevention and Policy"},{"key":"206_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2478\/nsad-2013-0025","volume":"30","author":"H Nokleby","year":"2013","unstructured":"Nokleby H. Use of doping agents and symptoms of eating disorders among male and female patients in drug addiction treatment. Nordic Stud Alcohol Drugs. 2013;30:331\u201346.","journal-title":"Nordic Stud Alcohol Drugs"},{"key":"206_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.drugalcdep.2010.04.020","volume":"111","author":"L Lundholm","year":"2010","unstructured":"Lundholm L, Kall K, Wallin S, Thiblin I. Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug Alcohol Depend. 2010;111:222\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"206_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.comppsych.2009.05.007","volume":"51","author":"F Klotz","year":"2010","unstructured":"Klotz F, Petersson A, Hoffman O, Thiblin I. The significance of anabolic androgenic steroids in a Swedish prison population. Compr Psychiatry. 2010;51:312\u20138.","journal-title":"Compr Psychiatry"},{"key":"206_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1515\/nsad-2015-0002","volume":"32","author":"D Sagoe","year":"2015","unstructured":"Sagoe D, Torsheim T, Molde H, Andreassen CS, Pallesen S. Anabolic-androgenic steroid use in the Nordic countries: a meta-analysis and meta-regression analysis. Nordic Stud Alcohol Drugs. 2015;32:7\u201320.","journal-title":"Nordic Stud Alcohol Drugs"},{"key":"206_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/sjop.12399","volume":"58","author":"D Sagoe","year":"2017","unstructured":"Sagoe D, Pallesen S, Andreassen CS. Prevalence and correlates of tattooing in Norway: a large-scale cross-sectional study. Scand J Psychol. 2017;58:562\u201370.","journal-title":"Scand J Psychol"},{"issue":"8","key":"206_CR16","doi-asserted-by":"publisher","first-page":"e0161208","DOI":"10.1371\/journal.pone.0161208","volume":"11","author":"JJ Rasmussen","year":"2016","unstructured":"Rasmussen JJ, Selmer C, \u00d8stergren PB, Pedersen KB, Schou M, Gustafsson F, Faber J, Juul A, Kistorp C. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study. PLoS One. 2016;11(8):e0161208.","journal-title":"PLoS One"},{"key":"206_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.fertnstert.2014.02.002","volume":"101","author":"CD Rahnema","year":"2014","unstructured":"Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid\u2013induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101:1271\u20139.","journal-title":"Fertil Steril"},{"key":"206_CR18","first-page":"167","volume":"76","author":"D Smit","year":"2018","unstructured":"Smit D, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. Neth J Med. 2018;76:167.","journal-title":"Neth J Med"},{"issue":"4","key":"206_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.biopsych.2016.06.017","volume":"82","author":"A Bj\u00f8rnebekk","year":"2016","unstructured":"Bj\u00f8rnebekk A, Walhovd KB, J\u00f8rstad ML, Due-T\u00f8nnessen P, Hullstein IR, Fjell AM. Structural brain imaging of long-term anabolic-androgenic steroid users and nonusing weightlifters. Biol Psychiatry. 2016;82(4):294\u2013302.","journal-title":"Biol Psychiatry"},{"key":"206_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1360-0443.1991.tb03101.x","volume":"86","author":"KJ Brower","year":"1991","unstructured":"Brower KJ, Blow FC, Young JP, Hill EM. Symptoms and correlates of anabolic-androgenic steroid dependence. Br J Addict. 1991;86:759\u201368.","journal-title":"Br J Addict"},{"key":"206_CR21","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1360-0443.2009.02734.x","volume":"104","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104:1966\u201378.","journal-title":"Addiction."},{"key":"206_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.drugalcdep.2010.01.011","volume":"109","author":"G Kanayama","year":"2010","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend. 2010;109:6\u201313.","journal-title":"Drug Alcohol Depend"},{"key":"206_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1037\/a0019370","volume":"18","author":"HG Pope","year":"2010","unstructured":"Pope HG, Kean J, Nash A, Kanayama G, Samuel DB, Bickel WK, Hudson JI. A diagnostic interview module for anabolic-androgenic steroid dependence: preliminary evidence of reliability and validity. Exp Clin Psychopharmacol. 2010;18:203\u201313.","journal-title":"Exp Clin Psychopharmacol"},{"key":"206_CR24","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.116.026945","volume":"135","author":"AL Baggish","year":"2017","unstructured":"Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, Pope HG. Cardiovascular toxicity of illicit anabolic-androgenic steroid UseClinical perspective. Circulation. 2017;135:1991\u20132002.","journal-title":"Circulation."},{"key":"206_CR25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3109\/10826084.2014.903751","volume":"49","author":"MA Pereira dos Santos","year":"2014","unstructured":"Pereira dos Santos MA, Coutinho de Oliveira CV, Silva AS. Adverse cardiovascular effects from the use of anabolic-androgenic steroids as ergogenic resources. Substance Use & Misuse. 2014;49:1132\u20137.","journal-title":"Substance Use & Misuse"},{"key":"206_CR26","doi-asserted-by":"crossref","unstructured":"Vanberg P, Atar D: Androgenic anabolic steroid abuse and the cardiovascular system. In Doping in Sports: Biochemical Principles, Effects and Analysis Springer; 2010: 411\u2013457.","DOI":"10.1007\/978-3-540-79088-4_18"},{"key":"206_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drugalcdep.2015.04.013","volume":"152","author":"I Thiblin","year":"2015","unstructured":"Thiblin I, Garmo H, Garle M, Holmberg L, Byberg L, Michaelsson K, Gedeborg R. Anabolic steroids and cardiovascular risk: a national population-based cohort study. Drug Alcohol Depend. 2015;152:87\u201392.","journal-title":"Drug Alcohol Depend"},{"key":"206_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.drugalcdep.2012.11.008","volume":"130","author":"G Kanayama","year":"2013","unstructured":"Kanayama G, Kean J, Hudson JI, Pope HG. Cognitive deficits in long-term anabolic-androgenic steroid users. Drug Alcohol Depend. 2013;130:208\u201314.","journal-title":"Drug Alcohol Depend"},{"key":"206_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.nicl.2016.11.014","volume":"13","author":"LT Westlye","year":"2017","unstructured":"Westlye LT, Kaufmann T, Aln\u00e6s D, Hullstein IR, Bj\u00f8rnebekk A. Brain connectivity aberrations in anabolic-androgenic steroid users. Neuroimage: Clinical. 2017;13:62\u20139.","journal-title":"Neuroimage: Clinical"},{"issue":"3","key":"206_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/joim.12850","volume":"285","author":"H Horwitz","year":"2018","unstructured":"Horwitz H, Andersen J, Dalhoff K. Health consequences of androgenic anabolic steroid use. J Intern Med. 2018;285(3):333\u201340.","journal-title":"J Intern Med"},{"key":"206_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1176\/appi.psy.46.4.285","volume":"46","author":"RC Hall","year":"2005","unstructured":"Hall RC, Hall RC, Chapman MJ. Psychiatric complications of anabolic steroid abuse. Psychosomatics. 2005;46:285\u201390.","journal-title":"Psychosomatics"},{"key":"206_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.eurpsy.2005.09.001","volume":"21","author":"TA Pagonis","year":"2006","unstructured":"Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. European Psychiatry. 2006;21:551\u201362.","journal-title":"European Psychiatry"},{"key":"206_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666141210222725","volume":"13","author":"D Piacentino","year":"2015","unstructured":"Piacentino D, Kotzalidis GD, del Casale A, Aromatario MR, Pomara C, Girardi P, Sani G. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Curr Neuropharmacol. 2015;13:101\u201321.","journal-title":"Curr Neuropharmacol"},{"key":"206_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/archpsyc.57.2.133","volume":"57","author":"HG Pope","year":"2000","unstructured":"Pope HG, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry. 2000;57:133\u201340.","journal-title":"Arch Gen Psychiatry"},{"key":"206_CR35","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1001\/archpsyc.63.11.1274","volume":"63","author":"F Klotz","year":"2006","unstructured":"Klotz F, Garle M, Granath F, Thiblin I. Criminality among individuals testing positive for the presence of anabolic androgenic Steroids. Arch Gen Psychiatry. 2006;63:1274\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"206_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.tins.2012.03.001","volume":"35","author":"JG Oberlander","year":"2012","unstructured":"Oberlander JG, Henderson LP. The Sturm und Drang of anabolic steroid use: angst, anxiety, and aggression. Trends Neurosci. 2012;35:382\u201392.","journal-title":"Trends Neurosci"},{"key":"206_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/add.12715","volume":"110","author":"L Lundholm","year":"2015","unstructured":"Lundholm L, Frisell T, Lichtenstein P, Langstrom N. Anabolic androgenic steroids and violent offending: confounding by polysubstance abuse among 10 365 general population men. Addiction. 2015;110:100\u20138.","journal-title":"Addiction."},{"key":"206_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.biopsych.2016.06.017","volume":"82","author":"A Bj\u00f8rnebekk","year":"2017","unstructured":"Bj\u00f8rnebekk A, Walhovd KB, J\u00f8rstad ML, Due-T\u00f8nnessen P, Hullstein IR, Fjell AM. Structural brain imaging of long-term anabolic-androgenic steroid users and nonusing weightlifters. Biol Psychiatry. 2017;82:294\u2013302.","journal-title":"Biol Psychiatry"},{"key":"206_CR39","unstructured":"Chandler M, McVeigh J. Steroids and Image Enhancing Drugs 2013 Survey Results. Centre for Public Health: Liverpool John Moores University; 2013."},{"key":"206_CR40","doi-asserted-by":"publisher","first-page":"e003207","DOI":"10.1136\/bmjopen-2013-003207","volume":"3","author":"VD Hope","year":"2013","unstructured":"Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergard A, Croxford S, Beynon CM, Parry JV, Bellis MA, Ncube F. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 2013;3:e003207.","journal-title":"BMJ Open"},{"key":"206_CR41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.drugalcdep.2009.12.024","volume":"109","author":"N Garevik","year":"2010","unstructured":"Garevik N, Rane A. Dual use of anabolic-androgenic steroids and narcotics in Sweden. Drug Alcohol Depend. 2010;109:144\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"206_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugpo.2018.02.022","volume":"55","author":"R Zahnow","year":"2018","unstructured":"Zahnow R, McVeigh J, Bates G, Hope V, Kean J, Campbell J, Smith J. Identifying a typology of men who use anabolic androgenic steroids (AAS). Int J Drug Policy. 2018;55:105\u201312.","journal-title":"Int J Drug Policy"},{"key":"206_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13011-015-0006-5","volume":"10","author":"D Sagoe","year":"2015","unstructured":"Sagoe D, McVeigh J, Bjornebekk A, Essilfie M-S, Andreassen CS, Pallesen S. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis. Substance Abuse Treatment, Prevention, and Policy. 2015;10:12.","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"206_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0091450917694268","volume":"44","author":"R Zahnow","year":"2017","unstructured":"Zahnow R, McVeigh J, Ferris J, Winstock A. Adverse effects, health service engagement, and service satisfaction among anabolic androgenic steroid users. Contemporary Drug Problems. 2017;44:69\u201383.","journal-title":"Contemporary Drug Problems"},{"key":"206_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1747-597X-3-24","volume":"3","author":"K Skarberg","year":"2008","unstructured":"Skarberg K, Nyberg F, Engstrom I. The development of multiple drug use among anabolic-androgenic steroid users: six subjective case reports. Subst Abuse Treat Prev Policy. 2008;3:24.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"206_CR46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/145507251002700610","volume":"27","author":"S Nesvaag","year":"2010","unstructured":"Nesvaag S, Lie T. The Norwegian substance treatment reform: between new public management and conditions for good practice. Nordic Stud Alcohol Drugs. 2010;27:655\u201366.","journal-title":"Nordic Stud Alcohol Drugs"},{"key":"206_CR47","unstructured":"The Norwegian Directorate of Health. 2017. Befolkningens bruk av TSB (The population's use of SUD treatment) \n                    https:\/\/statistikk.helsedirektoratet.no\/bi\/Dashboard\/d2e98a86-5c17-4e94-8d95-aa0d3e9fdf94?e=false&vo=viewonly\n                    \n                   Accessed 19 Mar 2019."},{"key":"206_CR48","unstructured":"The Norwegian Directorate of Health. 2015. Prioriteringsveileder for tverrfaglig spesialisert rusbehandling (priority guide for multidisciplinary specialized substance use treatment) \n                    https:\/\/www.helsedirektoratet.no\/veiledere\/prioriteringsveiledere\/tverrfaglig-spesialisert-rusbehandling-tsb\/tilstander-for-tverrfaglig-spesialisert-rusbehandling-tsb\/dopingandrogene-anabole-steroider\n                    \n                  . Accessed 19 Mar 2019."},{"key":"206_CR49","unstructured":"Oslo University hospital. 2018. Steroidelab. \n                    https:\/\/www.steroidelab.no\n                    \n                   Accessed 19. Mar 2019."},{"key":"206_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"206_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/bmj.320.7227.114","volume":"320","author":"C Pope","year":"2000","unstructured":"Pope C, Ziebland S, Mays N. Qualitative research in health care: analysing qualitative data. Br Med J. 2000;320:114.","journal-title":"Br Med J"},{"key":"206_CR52","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/j.fertnstert.2010.03.042","volume":"94","author":"I Pirola","year":"2010","unstructured":"Pirola I, Cappelli C, Delbarba A, Scalvini T, Agosti B, Assanelli D, Bonetti A, Castellano M. Anabolic steroids purchased on the internet as a cause of prolonged hypogonadotropic hypogonadism. Fertil Steril. 2010;94:2331.","journal-title":"Fertil Steril"},{"key":"206_CR53","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1186\/1477-7517-11-19","volume":"11","author":"A Kimergard","year":"2014","unstructured":"Kimergard A, McVeigh J. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study. Harm Reduct J. 2014;11:1492.","journal-title":"Harm Reduct J"},{"key":"206_CR54","doi-asserted-by":"publisher","unstructured":"Bilgrei OR. Broscience: creating trust in online drug communities. New Media Soc. 2017. \n                    https:\/\/doi.org\/10.1177\/1461444817730331\n                    \n                  .","DOI":"10.1177\/1461444817730331"},{"key":"206_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-017-0176-8","volume":"14","author":"B Tighe","year":"2017","unstructured":"Tighe B, Dunn M, McKay FH, Piatkowski T. Information sought, information shared: exploring performance and image enhancing drug user-facilitated harm reduction information in online forums. Harm Reduct J. 2017;14:48.","journal-title":"Harm Reduct J"},{"key":"206_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1017\/S0950268814000727","volume":"143","author":"V Hope","year":"2015","unstructured":"Hope V, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimerg\u00e5rd A, Parry J, Ncube F. Injection site infections and injuries in men who inject image-and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiology & Infection. 2015;143:132\u201340.","journal-title":"Epidemiology & Infection"},{"key":"206_CR57","volume-title":"Steroids and image enhancing drugs 2013 survey results. Liverpool: LJMU Centre for public health","author":"M Chandler","year":"2014","unstructured":"Chandler M, McVeigh J. Steroids and image enhancing drugs 2013 survey results. Liverpool: LJMU Centre for public health; 2014."},{"key":"206_CR58","doi-asserted-by":"publisher","unstructured":"J\u00f8rstad ML, Skogheim TS, Bergsund HB. \u201cMer hjelp, mindre moralpreken\u201d Hva brukere av anabole-androgene steroider \u00f8nsker fra helsetjenestene. Nordic Stud Alcohol Drugs. 2018. \n                    https:\/\/doi.org\/10.1177\/1455072517748871.47\n                    \n                  .","DOI":"10.1177\/1455072517748871.47"},{"key":"206_CR59","doi-asserted-by":"publisher","first-page":"e005275","DOI":"10.1136\/bmjopen-2014-005275","volume":"4","author":"A Kimerg\u00e5rd","year":"2014","unstructured":"Kimerg\u00e5rd A, McVeigh J. Environments, risk and health harms: a qualitative investigation into the illicit use of anabolic steroids among people using harm reduction services in the UK. BMJ Open. 2014;4:e005275.","journal-title":"BMJ Open"},{"key":"206_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bodyim.2015.06.001","volume":"15","author":"J Yu","year":"2015","unstructured":"Yu J, Hildebrandt T, Lanzieri N. Healthcare professionals' stigmatization of men with anabolic androgenic steroid use and eating disorders. Body Image. 2015;15:49\u201353.","journal-title":"Body Image"},{"key":"206_CR61","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1360-0443.2004.00781.x","volume":"99","author":"HG Pope","year":"2004","unstructured":"Pope HG, Kanayama G, lonescu-Pioggia M, Hudson JI. Anabolic steroid users' attitudes towards physicians. Addiction. 2004;99:1189\u201394.","journal-title":"Addiction."},{"key":"206_CR62","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/10401239909147074","volume":"11","author":"I Thiblin","year":"1999","unstructured":"Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry. 1999;11:223\u201331.","journal-title":"Ann Clin Psychiatry"},{"key":"206_CR63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1520\/JFS14635J","volume":"45","author":"I Thiblin","year":"2000","unstructured":"Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. Journal of Forensic Science. 2000;45:16\u201323.","journal-title":"Journal of Forensic Science"},{"key":"206_CR64","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/sms.12122","volume":"24","author":"AS Lindqvist","year":"2014","unstructured":"Lindqvist AS, Moberg T, Ehrnborg C, Eriksson B, Fahlke C, Ros\u00e9n T. Increased mortality rate and suicide in Swedish former elite male athletes in power sports. Scand J Med Sci Sports. 2014;24:1000\u20135.","journal-title":"Scand J Med Sci Sports"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-019-0206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13011-019-0206-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-019-0206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T19:23:11Z","timestamp":1589484191000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-019-0206-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1186\/s13011-019-0206-5","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The information service study with anonymous data, and the qualitative study with interview data, were assessed by the Regional Committee for Medical and Health Research Ethics as not requiring ethical approval. The data protection officer at Oslo University Hospital HF approved both studies (2016\/17604 and 2016\/12244). Participants in the qualitative part of the study signed an informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"20"}}